Full TitlePhase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)
The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment.
RP-6306 blocks the protein PKMY1, which plays a major role in the survival and growth of cancers with the genetic changes being studied in this clinical trial. RP-6306 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a locally advanced or metastatic solid tumor that has come back or continued to grow despite prior treatment.
- Participants’ tumors must contain a mutation in the FBXW7 or PPP2R1A genes or extra copies of the CCNE1 gene.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 12 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alison Schram at 646-888-5388.